Logan Coy Related postsA Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)September 11, 2026An Open-Label, Multicenter, Phase 1b/2 Study of KRT-232 Combined with Ruxolitinib in Primary Myelofibrosis, Post-PV-MF, or Post-ET-MF with Suboptimal Response to RuxolitinibSeptember 11, 2026A Phase 1, Open-Label, Multicenter Study of the Pharmacokinetics and Safety of Pralatrexate in Advanced Solid Tumor or Hematological Malignancy with Normal or Mild/Moderate/Severe Hepatic ImpairmentSeptember 11, 2026 Previous postA Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior TherapiesNext postA Phase 3, randomised, double-blind, placebo-controlled, multicentre trial comparing trilaciclib versus placebo in limited-stage small cell lung cancer